» Articles » PMID: 36106099

MTBP Enhances the Activation of Transcription Factor ETS-1 and Promotes the Proliferation of Hepatocellular Carcinoma Cells

Overview
Journal Front Oncol
Specialty Oncology
Date 2022 Sep 15
PMID 36106099
Authors
Affiliations
Soon will be listed here.
Abstract

Increasing evidence indicates that the oncoprotein murine double minute (MDM2) binding protein (MTBP) can be considered a pro-oncogene of human malignancies; however, its function and mechanisms in hepatocellular carcinoma (HCC) are still not clear. In the present work, our results demonstrate that MTBP could function as a co-activator of transcription factor E26 transformation-specific sequence (ETS-1), which plays an important role in HCC cell proliferation and/or metastasis and promotes proliferation of HCC cells. Using luciferase and real-time polymerase chain reaction (qPCR) assays, MTBP was found to enhance the transcription factor activation of ETS-1. The results from chromatin co-immunoprecipitation showed that MTBP enhanced the recruitment of ETS-1 to its downstream gene's (mmp1's) promoter region with ETS-1 binding sites. In cellular and nude mice models, overexpression of MTBP was shown to promote the proliferation of MHCC97-L cells with low endogenous MTBP levels, whereas the knockdown of MTBP led to inhibition of the proliferation of MHCC97-H cells that possessed high endogenous levels of MTBP. The effect of MTBP on ETS-1 was confirmed in the clinical specimens; the expression of MTBP was positively correlated with the downstream genes of ETS-1, , , and . Therefore, by establishing the role of MTBP as a novel co-activator of ETS-1, this work expands our knowledge of MTBP or ETS-1 and helps to provide new ideas concerning HCC-related research.

Citing Articles

Integrative analysis based on ATAC-seq and RNA-seq reveals a novel oncogene PRPF3 in hepatocellular carcinoma.

Bai Y, Deng X, Chen D, Han S, Lin Z, Li Z Clin Epigenetics. 2024; 16(1):154.

PMID: 39501301 PMC: 11539654. DOI: 10.1186/s13148-024-01769-w.


Xanthohumol overcomes osimertinib resistance via governing ubiquitination-modulated Ets-1 turnover.

Ma Y, Wang R, Liao J, Guo P, Wang Q, Li W Cell Death Discov. 2024; 10(1):454.

PMID: 39468027 PMC: 11519634. DOI: 10.1038/s41420-024-02220-y.


Transcription factor E2F4 facilitates SUMOylation to promote HCC progression through interaction with LIN9.

Ma Z, Li Q, Wang W, Deng Z Int J Oncol. 2024; 65(4).

PMID: 39239750 PMC: 11387118. DOI: 10.3892/ijo.2024.5686.


Characterization of an Hypomorphic Allele in a Diethylnitrosamine-Induced Liver Carcinogenesis Model.

Ranjan A, Thoenen E, Kaida A, Wood S, Van Dyke T, Iwakuma T Cancers (Basel). 2023; 15(18).

PMID: 37760565 PMC: 10526184. DOI: 10.3390/cancers15184596.

References
1.
Zheng B, Liu X, Fan R, Bai J, Wen H, Du L . The Landscape of Cell-Free HBV Integrations and Mutations in Cirrhosis and Hepatocellular Carcinoma Patients. Clin Cancer Res. 2021; 27(13):3772-3783. DOI: 10.1158/1078-0432.CCR-21-0002. View

2.
Feng F, Jiang Q, Cao S, Cao Y, Li R, Shen L . Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma. Biochim Biophys Acta Gen Subj. 2018; 1862(4):1017-1030. DOI: 10.1016/j.bbagen.2018.01.011. View

3.
Buhrmann C, Brockmueller A, Harsha C, Kunnumakkara A, Kubatka P, Aggarwal B . Evidence That Tumor Microenvironment Initiates Epithelial-To-Mesenchymal Transition and Calebin A can Suppress it in Colorectal Cancer Cells. Front Pharmacol. 2021; 12:699842. PMC: 8283792. DOI: 10.3389/fphar.2021.699842. View

4.
Cox T . The matrix in cancer. Nat Rev Cancer. 2021; 21(4):217-238. DOI: 10.1038/s41568-020-00329-7. View

5.
Alam M, Fatima N, Devi G, Ravins , Brojen Singh R . The enhancement of stability of p53 in MTBP induced p53-MDM2 regulatory network. Biosystems. 2012; 110(2):74-83. DOI: 10.1016/j.biosystems.2012.09.005. View